NCT06636435 - A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Solid TumorsHepatocellular Carcinoma (HCC)Malignant MelanomaPediatric Cancer

Interventions

DRUG

CBA-1205 Part 1

CBA-1205: 0.1, 0.3, 1, 3, 10, 20, 30 mg/kg (Intravenous solution)

DRUG

CBA-1205 Part 2

CBA-1205: 20 mg/kg and 30 mg/kg (Intravenous solution)

DRUG

CBA-1205 Part 3

CBA-1205: 30 mg/kg (Intravenous solution)

DRUG

CBA-1205 Part 4

CBA-1205: 20 mg/kg (Intravenous solution)

DRUG

CBA-1205 Part 5

CBA-1205: 10 mg/kg (The initial cohort, Intravenous solution)

Trial Locations (5)

RECRUITING

National Cancer Center Hospital East, Kashiwa

RECRUITING

Kanagawa Cancer Center, Yokohama

RECRUITING

Niigata University Medical and Dental Hospital, Niigata

RECRUITING

National Cancer Center Hospital, Chūō

RECRUITING

University of Yamanashi Hospital, Chūō